Lorlatinib 100mg Tablets $150

Lorlatinib is a third-generation ALK and ROS1 inhibitor indicated for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) after progression on prior ALK inhibitors. It zero’s in on ALK and ROS1 kinases to stop tumors from growing. You’ve got two types of the tablets: 25 mgs and 100 mgs.

You should aim for 100 mgs a day, whether you grab it with grub or not. Each bottle you’ll find comes packed with 30 little tablets. It does its thing by getting in the way of certain kinase activities that fuel those ALK and ROS1 proteins we’re talking about—they’re often hanging around in lung cancer cells.

Using its ‘targeted’ skills, it aims to slow down tumor growth and ease symptoms caused by NSCLC. Being the third go-around, Lorlatinib is believed to be way cooler—and, I mean, more effective—than the ones that came before. Keep an eye on the side effects, which can be a bit of a headache—like diarrhea, yukky nausea, and general tiredness.

It can also mess with your lungs. Lorlatinib is a big player in the field of personalized cancer medicine, giving patients something that’s specifically right for them if they’ve got certain mutations that’s the beast fueling their disease.